sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(33)

<< < 1 | 2 > >>

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization
D. Fukumura, and R. K. Jain Microvasc.Res. 74(2-3):72-84 (2007)
to & Angiogenesis Animals Blood Endothelial Factors Growth Humans Inhibitors Laboratories Neoplasms Neovascularization Pathologic Research Vascular Vessels antagonists blood cells drug inhibitors pathology supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib
S. E. Deprimo, and C. Bello Ann.Oncol (2007)
to Angiogenesis Biological Cells Endothelial Growth Humans Indoles Inhibitors Laboratories Markers Neoplasms Neovascularization Pathologic Proteins Pyrroles Research Tumor blood cells diagnosis drug effects metabolism methods pathology pharmacology protein response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular and cellular biomarkers for angiogenesis in clinical oncology
F. Bertolini, P. Mancuso, Y. Shaked, and R. S. Kerbel Drug Discov.Today 12(19-20):806-812 (2007)
to Angiogenesis Antigens Biological Cells Endothelial Humans Inhibitors Markers Microcirculation Neoplasms Neovascularization Pathologic Research Tumor blood cells diagnosis drug metabolism pathology pharmacology supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib
E. Chorianopoulos, D. Jager, H. A. Katus, and N. Frey Clin.Res.Cardiol. 96(11):829-830 (2007)
to & Aged Agents Angiogenesis Antineoplastic Carcinoma Cardiomyopathies Cell Dysfunction Echocardiography Female Humans Illness Index Indoles Inhibitors Kidney Kinase Kinases Left Neoplasms Protein-Tyrosine Pyrroles Renal Severity Tyrosine Ventricular adverse antagonists chemically contraindications drug effects induced inhibitors of therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Angiogenesis: an organizing principle for drug discovery?
J. Folkman Nat.Rev.Drug Discov. 6(4):273-286 (2007)
to Agents Angiogenesis Animals Antineoplastic Blood Endothelium Humans Inhibitors Neoplasms Neovascularization Pathologic Physiologic Platelets RANGE Research drug effects genetics pathology pharmacology physiology therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular basis for sunitinib efficacy and future clinical development
S. Faivre, G. Demetri, W. Sargent, and E. Raymond Nat.Rev.Drug Discov. 6(9):734-745 (2007)
to & A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications
J. Harper, and M. A. Moses EXS (2006)
to & Angiogenesis Capillaries Human Humans Inhibitors Neoplasms Neovascularization Pathologic Research blood control drug metabolism pathology pharmacology prevention supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a review
F. A. Eskens, and J. Verweij Eur.J.Cancer 42(18):3127-3139 (2006)
to & A Angiogenesis Antibodies Endothelial Factor Growth Humans Inhibitors Kinase Kinases Medical Monoclonal Neoplasms Neovascularization Oncology Pathologic Protein Protein-Tyrosine Receptors Tyrosine Vascular adverse antagonists blood control drug effects inhibitors prevention protein supply therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions
A. Morabito, Maio E. De, Maio M. Di, N. Normanno, and F. Perrone Oncologist. 11(7):753-764 (2006)
to & A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Notch signaling in the regulation of tumor angiogenesis
A. O. Rehman, and C. Y. Wang Trends Cell Biol. 16(6):293-300 (2006)
to & Agents Angiogenesis Animals Binding Biological Blood Carcinogens Cells Endothelial Genes Humans Inducing Inhibitors Laboratories Ligands Models Neoplasms Neovascularization Notch Pathologic Receptors Signal Suppressor Transduction Tumor Vessels blood cells development growth metabolism physiology supply therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
H. M. Verheul, and H. M. Pinedo Nat.Rev.Cancer 7(6):475-485 (2007)
to & A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Home blood-pressure monitoring in patients receiving sunitinib
M. Azizi, A. Chedid, and S. Oudard N.Engl.J.Med. 358(1):95-97 (2008)
to Agents Ambulatory Angiogenesis Antineoplastic Blood Carcinoma Cell Heart Home Humans Hypertension Indoles Inhibitors Kidney Kinase Kinases Monitoring Neoplasms Nursing Pressure Protein-Tyrosine Pyrroles Rate Receptor Renal Telemedicine adverse chemically diagnosis drug effects induced therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Clinical biomarkers of angiogenesis inhibition
A. P. Brown, D. E. Citrin, and K. A. Camphausen Cancer Metastasis Rev. 27(3):415-434 (2008)
to Angiogenesis Human Inhibitors Research response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive
V. Brower J.Natl.Cancer Inst. 101(12):846-847 (2009)
to A Analysis Angiogenesis Animals Antibodies Benzenesulfonates Biological Cells Cytokines Disease-Free Endothelial Factor Growth Humans Indoles Inhibitors Markers Monoclonal Neoplasms Pyridines Pyrroles Survival Tumor Vascular blood drug effects metabolism mortality pathology pharmacology response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom J.Clin.Oncol. 27(25):4169-4176 (2009)
to & A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Antiangiogenesis research is booming, as questions and studies proliferate
V. Brower J.Natl.Cancer Inst. 101(11):780-781 (2009)
to & Administration Analysis Angiogenesis Antibodies Antineoplastic Biological Chemotherapy Colorectal Combined Controlled Drug Humans Inhibitors Markers Monoclonal Neoplasms Pericytes Protocols Randomized Research Schedule Survival Topic Trials Tumor administration analysis as blood dosage drug effects mortality supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
R. Kumar, M. C. Crouthamel, D. H. Rominger, R. R. Gontarek, P. J. Tummino, R. A. Levin, and A. G. King Br.J.Cancer 101(10):1717-1723 (2009)
to & 3 50 Angiogenesis Benzenesulfonates Bone Cell Cells Concentration Diseases Endothelial Factor Growth Hematologic Hematopoietic Human Humans Indoles Inhibitors Inhibitory Kinase Line Marrow Myelopoiesis Phosphorylation Platelet-Derived Protein Proteins Proto-Oncogene Pyridines Pyrimidines Pyrroles Receptors Research Specificity Stem Substrate Sulfonamides Tumor Tyrosine Vascular antagonists c-kit chemically drug effects enzymology fms-Like induced inhibitors methods pharmacology protein by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Biomarkers of response and resistance to antiangiogenic therapy
R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu, J. S. Loeffler, T. T. Batchelor, and A. G. Sorensen Nat.Rev.Clin.Oncol. 6(6):327-338 (2009)
to & A Angiogenesis Biological Drug Endothelial Factor Growth Humans Hypertension Inhibitors Markers Neoplasm Neoplasms Neovascularization Pathologic Research Resistance Tumor Vascular antagonists blood control inhibitors metabolism prevention response supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
C. Sessa, A. Guibal, Conte G. Del, and C. Ruegg Nat.Clin.Pract.Oncol. 5(7):378-391 (2008)
to Angiogenesis Antibodies Benzenesulfonates Biological Clinical Humans Indoles Inhibitors Markers Monoclonal Neoplasms Neovascularization Pathologic Pyridines Pyrroles Research Topic Trials Tumor as drug metabolism therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 | 2 > >>publications per page: 5 10 20 50 100

a gripper